TWST | Ticker Profile - Titan Protect

TWST

Twist Bioscience Corporation

Healthcare · Diagnostics & Research · NMS

$69.22

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.0B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-31.30

Based on estimated future earnings — lower means cheaper

Rev Growth

+19.3%

Year-over-year revenue change

Profit Margin

-19.8%

How much profit the company keeps from each dollar of revenue

ROE

-18.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$65.00

-6% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

https://www.twistbioscience.com

Country: United States Employees: 979 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.732

Good returns relative to risk taken

Kelly Fraction

0.0572

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.517

Acceptable balance between returns and drawdown risk

Annual Return

30.5%

Historical annualised return based on price data

Max Drawdown

-59.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.23

Significantly more volatile than the market

52W High

$66.94

-3% below the year high

52W Low

$23.30

197% above the year low

Avg Volume

1,292,196

Average daily shares traded — higher means easier to buy and sell

Short Ratio

11.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

34.2%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.32

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.36

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.70

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.04

Like current ratio but excludes inventory — stricter test

Gross Margin

52.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-34.9%

Profit from core operations before interest and tax

Free Cash Flow

$-58,482,500

Negative — the business is spending more than it generates

Revenue (TTM)

$409M

Total revenue over the last 12 months

Net Income

$-81,276,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$80.00

Target Median

$65.00

Target Low

$36.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go